Franklin Genomic Advancements ETFFranklin Genomic Advancements ETFFranklin Genomic Advancements ETF

Franklin Genomic Advancements ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪11.25 M‬USD
Fund flows (1Y)
‪1.28 M‬USD
Dividend yield (indicated)
Discount/Premium to NAV
0.7%

About Franklin Genomic Advancements ETF


Issuer
Franklin Resources, Inc.
Brand
Franklin
Expense ratio
0.50%
Inception date
Feb 25, 2020
Index tracked
No Underlying Index
Management style
Active
HELX invests in global companies benefitting from the advancements of genomic-based research techniques and technologies that are designed to extend or enhance the quality of life. The fund advisor uses fundamental research to identify and select stocks they feel best positioned to capitalize on such genomic advancements. Companies may include those that research, develop, produce or manufacture bionic devices, molecular medicine, pharmaceuticals and agricultural applications. HELX is one of the first three thematic funds to launch from Franklin Templeton.

Classification


Asset Class
Equity
Category
Sector
Focus
Theme
Niche
Genomic advancements
Strategy
Active
Weighting scheme
Proprietary
Selection criteria
Proprietary

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of October 17, 2024
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.32%
Health Technology81.42%
Commercial Services9.53%
Health Services2.96%
Process Industries2.77%
Technology Services2.49%
Finance0.16%
Bonds, Cash & Other0.68%
Cash0.68%
Stock breakdown by region
92%4%3%
North America92.13%
Europe4.05%
Asia3.82%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows